At a glance
- Originator Kyowa Hakko
- Class Anti-inflammatories; Pyrimidinones; Quinazolines
- Mechanism of Action Adenosine deaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Inflammation in Japan (PO)
- 07 May 2002 Preclinical trials in Inflammation in Japan (PO)